Jesduvroq: Withdrawal of the marketing authorisation application


GlaxoSmithKline Trading Services Limited withdrew its application for a marketing authorisation of Jesduvroq for the treatment of adult patients with symptoms of anaemia caused by chronic kidney disease.

The company withdrew the application on 12 July 2023.

Key facts

Product number
Active substance
  • daprodustat
Date of withdrawal
Company making the application
GlaxoSmithKline Trading Services Limited
Withdrawal type
Initial authorisation

Related information on withdrawals

A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

How useful was this page?

Add your rating